ViaCyte Provides Update on Patent Portfolio in Stem Cell-Derived Cell Replacement Therapies for Type 1 Diabetes and Other Indications

ViaCyte, Inc. today announced 165 new patents were issued in 2018. These issued patents provide protection to the Company’s core technologies in the United States, European Union, and other jurisdictions around the world and further reinforce ViaCyte